Immutep Ltd ADR (IMMP) Stock Price, Quote & News

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 8315 7003

Fax: 61 2 8569 1880

Website: www.immutep.com

Address:

Australia Square, Level 32 264 George Street, Sydney, Australia

LolaRoss Oct. 26 at 7:57 AM

$IMMP Success takes time and requires consistent effort. You won't achieve it all at once. Stay focused and keep working step by step @LolaRoss

1 · Reply

IFeelLike Oct. 24 at 2:14 PM

$IMMP so what's next? November CTOS, again.... the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida. and the first serious cash generator and stock lifter I guess.... For Tacti-004 major update early 2026 CEO: Immutep Chief Executive Officer, Marc Voigt, said, “We are very pleased with the pace of enrolment in our pivotal Phase III trial that we believe has the potential to change the treatment landscape in non-small cell lung cancer, one of the largest indications in oncology with over two million diagnoses annually worldwide. The trial remains on track for key milestones ahead including futility analysis in early 2026.”

0 · Reply

TheIrishCzar Oct. 23 at 8:40 PM

$IMMP interest rate/income rate for borrowed shares at broker changed up to 17.5 today. This has been very very good for the last couple years.

0 · Reply

theinvestaar Oct. 23 at 8:22 PM

$IMMP AfterHours!

1 · Reply

bylocehi Oct. 23 at 1:31 PM

$IMMP Mr AI says ”While a presentation on eftilagimod alfa (efti) at the San Antonio Breast Cancer Symposium (SABCS) 2025 is possible, it is not confirmed. The manufacturer, Immutep, and investigators have recently presented and published data from its phase II/III AIPAC-003 trial, which studies efti in metastatic breast cancer. Abstracts will be announced October 30” so we wait

1 · Reply

IFeelLike Oct. 22 at 7:07 PM

$IMMP everybody winning and losing at Beyond Meat? Again 2 billion stocks traded, that's 25 times the stocks available...bizarrrrrr Anyway, still patient for Immp, up to the next conference in november

0 · Reply

Geauxtigers47 Oct. 22 at 2:50 PM

$IMMP you’re welcome for the dip- I added lol

1 · Reply

LAG3boom Oct. 22 at 2:17 AM

$IMMP Amigos, little disappointed bout upcoming 5000% return with the stock. Hoping 4 10,000% return. What you think?

1 · Reply

theinvestaar Oct. 22 at 1:02 AM

$IMMP That is HUGE.

2 · Reply

Nico07 Oct. 21 at 4:00 PM

$IMMP 3 X better than standard of care! Let’s go Immutep!

0 · Reply

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Jul 30, 2025, 8:00 AM EDT - 3 months ago

Immutep Quarterly Activities Report Q4 FY25

Jul 29, 2025, 8:00 AM EDT - 3 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

May 27, 2025, 8:00 AM EDT - 5 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 15, 2025, 3:50 PM EDT - 5 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 8, 2025, 8:46 AM EDT - 6 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Immutep to Participate in Upcoming Investor Conferences

Jan 31, 2025, 8:00 AM EST - 9 months ago

Immutep Quarterly Activities Report Q2 FY25

Jan 28, 2025, 4:37 PM EST - 9 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Dec 17, 2024, 8:00 AM EST - 11 months ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 12, 2024, 8:15 AM EST - 11 months ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Nov 15, 2024, 3:18 PM EST - 1 year ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 14, 2024, 11:16 AM EST - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 7, 2024, 9:10 AM EDT - 1 year ago

Immutep: Navigating The Bumps In The Road

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Jul 15, 2024, 1:54 PM EDT - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 2, 2024, 8:38 PM EDT - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

May 15, 2024, 8:00 AM EDT - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 2, 2024, 8:00 AM EDT - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Jan 30, 2024, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY24

Jan 4, 2024, 8:00 AM EST - 1 year ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 3, 2024, 5:04 PM EST - 1 year ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

LolaRoss Oct. 26 at 7:57 AM

$IMMP Success takes time and requires consistent effort. You won't achieve it all at once. Stay focused and keep working step by step @LolaRoss

1 · Reply

IFeelLike Oct. 24 at 2:14 PM

0 · Reply

TheIrishCzar Oct. 23 at 8:40 PM

$IMMP interest rate/income rate for borrowed shares at broker changed up to 17.5 today. This has been very very good for the last couple years.

0 · Reply

theinvestaar Oct. 23 at 8:22 PM

$IMMP AfterHours!

1 · Reply

bylocehi Oct. 23 at 1:31 PM

1 · Reply

IFeelLike Oct. 22 at 7:07 PM

0 · Reply

Geauxtigers47 Oct. 22 at 2:50 PM

$IMMP you’re welcome for the dip- I added lol

1 · Reply

LAG3boom Oct. 22 at 2:17 AM

$IMMP Amigos, little disappointed bout upcoming 5000% return with the stock. Hoping 4 10,000% return. What you think?

1 · Reply

theinvestaar Oct. 22 at 1:02 AM

$IMMP That is HUGE.

2 · Reply

Nico07 Oct. 21 at 4:00 PM

$IMMP 3 X better than standard of care! Let’s go Immutep!

0 · Reply

theinvestaar Oct. 21 at 1:40 PM

$IMMP this company is worth billions in the future. So many different tumor types so much success to come.

0 · Reply

NOCKNOCK Oct. 21 at 1:35 PM

$IMMP is the one!

0 · Reply

ToRni27 Oct. 21 at 12:18 PM

$IMMP ChatGPT could not find a better cancer stock. First IOVA lung cancer results in very small cohort 55-65% ORR. IOVA got a drug that is very hard to scale and will never supply all patients on the market that need it. Second IBRX still unknown - they even added another drug in phase 3 seems like results were not good. Third SMMT showed worse results in western countries than in china so its unkown if data is accurate.

0 · Reply

ToRni27 Oct. 21 at 4:37 AM

$IMMP Efti is strong with and without chemo. People could choose between chemo free or with chemo but ofc triple combination is more effective. https://www.immutep.com/dw/uploads/2025/08/IMM_Corp_Pres_2025_06_02-1.pdf

0 · Reply

rispi Oct. 20 at 6:18 PM

$IMMP

0 · Reply

RedemptionwithGod Oct. 20 at 3:27 PM

$IMMP

0 · Reply

SeatownGreen Oct. 20 at 2:47 PM

$IMMP There’s data coming up soon that can help with business development. Let’s make a deal. I don’t know what we’ll see, but turning Sarcoma hot would bring virtually all eyeballs to this trial. This data will apply to eftilagimod alpha in all settings if the mechanism of action is demonstrated.👊

2 · Reply

Tdorsey1776 Oct. 20 at 1:20 PM

$IMMP Shall we assume the stock will pull back AGAIN???

1 · Reply

Gabriel_DS Oct. 20 at 1:18 PM

$IMMP just give us a BO so we can move on after years and years. We know it works and all is great but SP is just crap and will likely stay crap after more good news

1 · Reply

Tdorsey1776 Oct. 20 at 12:53 PM

$IMMP The investigator-initiated Phase II study evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) met the primary endpoint and significantly exceeded the study’s prespecified 35% tumour hyalinization/fibrosis. In the evaluable patient population (N=38), the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis (p<0.001). This impressive outcome, over three times greater than 15% from standard-of-care radiotherapy alone based on historical data, may hold significance in terms of future outcomes as tumour hyalinization/fibrosis serves as an early surrogate endpoint correlated with enhanced overall survival and recurrence-free survival in STS patients.1,2 These promising results were achieved across multiple STS subtypes and the study proved a very good safety profile for the therapy, with only one grade ≥3 toxicity related to immunotherapy.

0 · Reply

GoldenVisions Oct. 20 at 12:50 PM

$VRME we have 2 prs thats due, compliance and the crypto strategy pr, it's a no brainer to add more here. This. thing has so much going for itself. $XBP $BGLC $IMMP $AZTR

0 · Reply

BigPennyStockAlerts Oct. 20 at 12:10 PM

$IMMP Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

0 · Reply

Market Cap	300.27M
Revenue (ttm)	6.69M
Net Income (ttm)	-39.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-594.62%
Debt to Equity Ratio	0.01

Volume	61,400
Avg Vol	132,070
Day's Range	N/A - N/A
Shares Out	147.19M
Stochastic %K	25%
Beta	1.87
Analysts	Strong Sell
Price Target	$9.50